Cell, gene, and tissue therapies continue to be the fastest growing fields in the biopharmaceutical industry.
These advanced medicines are treating complex diseases and conditions such as cancer, tissue injuries, and revolutionary vaccines.
But significant processing and analytical challenges remain, however.
Every year, Informa Connect invites cell, gene, and tissue therapy industry representatives meet to discuss best practices and best strategies for overcoming those challenges.
Like most meetings in 2020, the Cell and Gene Bioprocessing and Commercialization conference was offered entirely online.
During 19–22 October, participants were invited to listen to presentations, plenaries, speaker panels, and even live virtual laboratory tours.
The five tracks were cell therapies, in vivo gene therapies, ex vivo gene-edited cell therapies, and advanced tools for cell and tissue manufacturing.
This report highlights a few presentations and speaker panels (by topic).
From investment trends and standardization to immunotherapy and the impacts of COVID-19, Maribel Rios reflects on the most popular live sessions across the week.
Maribel Rios reviews the top sessions from the biggest track of the event, including automated analytics and autologous CAR-T cell therapy.
We look back at a popular talk exploring next generation cell-line development and recombinant adenoassociated virus production.
Maribel Rios highlights key takeaways from the track's hottest panel, which discussed gene modified allogeneic MSCs and NK Cells.
We explore presentations showcasing diverse tissue engineering applications and automated cell harvesting.
